Free Trial

ImmunoCellular Therapeutics (IMUCD) Stock Chart & Stock Price History

$0.08 +0.00 (+4.75%)
As of 07/11/2025

ImmunoCellular Therapeutics Stock Price Performance

The ImmunoCellular Therapeutics (IMUCD) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 18.80%, with a year-to-date return of -54.30%. In the past month, the stock has decreased 28.44%, reflecting recent market activity.

As of the latest close, ImmunoCellular Therapeutics traded at $0.07 with a market cap of and volume of 433 shares.

Receive IMUCD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoCellular Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

5 Day
Performance
+14.96%
1 Month
Performance
-28.44%
3 Month
Performance
-48.19%
Year-To-Date
Performance
-54.30%
1 Year
Performance
-18.80%

IMUCD Stock Chart for Sunday, July, 13, 2025

ImmunoCellular Therapeutics Stock Price History

DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization
07/11/2025$0.07$0.07
+9.76%
$0.07$0.07433 shs$0.00
07/10/2025$0.07$0.07$0.07$0.0722 shs$0.00
07/09/2025$0.07$0.07$0.07$0.0722 shs$0.00
07/08/2025$0.07$0.07
-5.63%
$0.07$0.07527 shs$0.00
07/04/2025$0.10$0.10$0.10$0.10220 shs$426,000.00
07/03/2025$0.10$0.10$0.10$0.10220 shs$426,000.00
07/02/2025$0.10$0.10$0.10$0.10220 shs$426,000.00
07/01/2025$0.07$0.10
+51.42%
$0.10$0.10220 shs$426,000.00
06/30/2025$0.07$0.07$0.07$0.071,917 shs$281,000.00
06/27/2025$0.06$0.06$0.06$0.06575 shs$258,000.00
06/26/2025$0.06$0.06$0.06$0.06575 shs$258,000.00
06/25/2025$0.10$0.06
-40.99%
$0.06$0.06575 shs$258,000.00
06/24/2025$0.10$0.10$0.10$0.105 shs$437,000.00
06/23/2025$0.10$0.10$0.10$0.10115 shs$437,000.00
06/20/2025$0.10$0.10
-0.48%
$0.10$0.06601 shs$437,000.00
06/16/2025$0.10$0.10$0.10$0.10100 shs$439,000.00
06/13/2025$0.11$0.11
+0.94%
$0.11$0.1116 shs$452,000.00
06/12/2025$0.11$0.11$0.11$0.11100 shs$447,000.00

This page (OTCMKTS:IMUCD) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners